A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma, Science, vol.254, pp.1643-1647, 1991. ,
Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes, Proc. Natl. Acad. Sci. USA, vol.101, issue.2, pp.14639-14645, 2004. ,
Immunotherapy of established (pre) malignant disease by synthetic long peptide vaccines, Nat. Rev. Cancer, vol.8, pp.351-360, 2008. ,
Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL, J. Immunol, vol.165, pp.948-955, 2000. ,
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma, Nat. Med, vol.4, pp.321-327, 1998. ,
Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients, Cancer Res, vol.60, pp.4499-4506, 2000. ,
Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues, J. Immunol, vol.160, pp.1750-1758, 1998. ,
Modified peptides in anti-cancer vaccines: are we eventually improving anti-tumour immunity?, Cancer Immunol. Immunother, vol.58, pp.1159-1167, 2009. ,
Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen, Proc. Natl. Acad. Sci. USA, vol.105, pp.3849-3854, 2008. ,
CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity, J. Immunol, vol.179, pp.5033-5040, 2007. ,
Long-lasting cross-presentation of tumor antigen in human DC, Eur. J. Immunol, vol.39, pp.380-390, 2009. ,
Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide, Proc. Natl. Acad. Sci. USA, vol.88, pp.2283-2287, 1991. ,
Infusion of Melan-A/Mart-1 specific tumor-infiltrating lymphocytes enhanced relapse-free survival of melanoma patients, Cancer Immunol. Immunother, vol.56, pp.515-526, 2007. ,
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes, Science, vol.298, pp.850-854, 2002. ,
Treatment of metastatic melanoma with autologous Melan-A/MART-1-specific cytotoxic T lymphocyte clones, J. Invest. Dermatol, vol.129, pp.2835-2842, 2009. ,
URL : https://hal.archives-ouvertes.fr/inserm-02481977
Cancer regression in patients after transfer of genetically engineered lymphocytes, Science, vol.314, pp.126-129, 2006. ,
Adoptive transfer of tumor-reactive Melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional Melan-A-specific T cells, J. Immunol, vol.175, pp.4797-4805, 2005. ,
URL : https://hal.archives-ouvertes.fr/inserm-02482064
Enumeration of human antigen-specific naive CD8+ T cells reveals conserved precursor frequencies, Blood, vol.115, pp.3718-3725, 2010. ,
URL : https://hal.archives-ouvertes.fr/pasteur-01402100
Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHCtumor peptide interactions, J. Exp. Med, vol.183, pp.2403-2407, 1996. ,
Efficient detection and immunomagnetic sorting of specific T cells using multimers of MHC class I and peptide with reduced CD8 binding, Nat. Med, vol.6, pp.707-710, 2000. ,
Importance of MHC class 1 alpha2 and alpha3 domains in the recognition of self and non-self MHC molecules, J. Immunol, vol.156, pp.2473-2480, 1996. ,
A novel population of human melanoma-specific CD8 T cells recognizes Melan-AMART-1 immunodominant nonapeptide but not the corresponding decapeptide, J. Immunol, vol.179, pp.7635-7645, 2007. ,
Optimal activation of tumor-reactive T cells by selected antigenic peptide analogues, Int. Immunol, vol.11, pp.1971-1980, 1999. ,
T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases, Nature, vol.427, pp.154-159, 2004. ,
Structural and kinetic basis for heightened immunogenicity of T cell vaccines, J. Exp. Med, vol.201, pp.1243-1255, 2005. ,
Melan-A/ MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers, J. Immunol, vol.177, pp.6769-6779, 2006. ,
Monocyte-derived dendritic cells formed at the infection site control the induction of protective T helper 1 responses against Leishmania, Immunity, vol.26, pp.519-531, 2007. ,
Plasmacytoid dendritic cells efficiently cross-prime naive T cells in vivo after TLR activation, Blood, vol.112, pp.3713-3722, 2008. ,
Degeneracy of antigen recognition as the molecular basis for the high frequency of naive A2/Melan-a peptide multimer(+) CD8(+) T cells in humans, J. Exp. Med, vol.196, pp.207-216, 2002. ,
Melan-A/MART-1-specific CD8 T cells: from thymus to tumor, Trends Immunol, vol.23, pp.325-328, 2002. ,
Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1, Clin. Cancer Res, vol.9, pp.669-677, 2003. ,
Therapeutic vaccination against human papilloma virus induced malignancies, Curr. Opin. Immunol, vol.23, pp.252-257, 2011. ,
Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia, N. Engl. J. Med, vol.361, pp.1838-1847, 2009. ,
Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses, Proc. Natl. Acad. Sci. USA, vol.107, pp.11895-11899, 2010. ,
Adoptive cell therapy for the treatment of patients with metastatic melanoma, Curr. Opin. Immunol, vol.21, pp.233-240, 2009. ,
Durable complete responses in heavily pretreated patients with metastatic melanoma using T cell transfer immunotherapy, Clin. Cancer Res, vol.17, pp.4550-4557, 2011. ,
Naive precursor frequencies and MHC binding rather than the degree of epitope diversity shape CD8+ T cell immunodominance, J. Immunol, vol.181, pp.2124-2133, 2008. ,